ReviewVaccines2021
Strategies for Enhancement of Live-Attenuated
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Combatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination.BMC infectious diseases · 2025Pooled it
- An Oral Vaccine Derived from AttenuatedVaccines · 2026Article
- Self-destructing attenuated adjuvant Salmonella serves as a safe and potent live vaccine adjuvant.NPJ vaccines · 2026Article
- Antimicrobial peptide resistance in Salmonella AMR: the role of surface binding and lipopolysaccharide remodelling: one health implications.World journal of microbiology & biotechnology · 2026Review
- Biological treatments for zoonotic salmonellosis: an evolving therapeutic landscape.Frontiers in microbiology · 2026Review
- Microbial Biotechnology in Medicine.Progress in molecular and subcellular biology · 2026Review
- Engineered Clostridium butyricum: a promising application of synthetic biology in comprehensive health.Microbial cell factories · 2025Review
- Bivalent Oral Vaccine Using AttenuatedVaccines · 2025Article
- Antiviral Immune Responses Against Murine Cytomegalovirus Induced by an OralMicroorganisms · 2025Article
- Oral Vaccination with AttenuatedPathogens (Basel, Switzerland) · 2025Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- Article
- Live-AttenuatedVaccines · 2023Article
- Evaluation ofVaccines · 2022Article
- Mucosal Vaccination: A Promising Alternative Against Flaviviruses.Frontiers in cellular and infection microbiology · 2022Review
- Development of a Trivalent Construct Omp18/AhpC/FlgH Multi Epitope Peptide Vaccine AgainstFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The use of live-attenuated bacterial vaccines as carriers for the mucosal delivery of foreign antigens to stimulate the mucosal immune system was first proposed over three decades ago. This novel strategy aimed to induce immunity against at least two distinct pathogens using a single bivalent carrier vaccine. It was first tested using a live-attenuated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.